Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
P/E ratio for Pulse Biosciences, Inc. (PLSE)
P/E ratio as of 2023: -13.93
According to Pulse Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -13.93. At the end of 2022 the company had a P/E ratio of -1.59.
P/E ratio history for Pulse Biosciences, Inc. from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -13.93 |
| 2022 | -1.59 |
| 2021 | -6.56 |
| 2020 | -11.15 |
| 2019 | -6.05 |
| 2018 | -5.21 |
| 2017 | -13.62 |
| 2016 | -7.52 |
| 2015 | -11.22 |
| 2014 | -22.05 |